this from an e-mail sent out by the livestock spec. with sask ag. no wonder everybody is suspicious of the americans.
In Sandy Russel's report on the Alberta Beef Industry Conference, Dr. Joyce VanDonkersgoed (AB Verified Beef program)was asked "If our industries are so linked why are we finding BSE cases and the US is not even though they have tested a higher number of animals?` Her comment was the "gold standard" tests (final confirmatory tests) in Canada and the US are different. She said the US version uses a test with 1 micoclonal antibody, compared to Canada's test which uses 15 microclonal antibodies. This could account for the difference.
The CFIA was asked to explain why Canada and the US would use different standards and why this has not been a issue in the debate over Canada being a source of BSE and the US is clean according to some of the opposition to the opening of the US border to Canadian cattle.
Following is the reply:
-----Original Message-----
From: Penny Greenwood [mailtogreenwood@inspection.gc.ca]
Sent: Wednesday, March 16, 2005 1:58 PM
To: jarmstrong@agr.gov.sk.ca
Cc: Nancy Lalonde; Marlene Longtin; <
Subject: Re: Testing for BSE- Canada and US proceedures: WEB RESPONSE / RÉPONSE DU WEB ID:2005/3-603
The international standard setting body for animal health and zoosanitary status is the OIE. This body sets the standards for conditions for countries to claim a particular disease status (eg. free) for specific diseases, stipulates conditions for trade in affected commodities (animals, semen, meat, etc), surveillance and also for diagnostic methodologies used to detect these diseases.
A member country could certainly debate the appropriateness of another member country's testing if they were not following the recommendations made in the OIE code and associated documentation.
Both the US and Canada utilize immunohistochemistry (IHC) as the gold standard test for BSE. In response to your comments regarding the antibodies used in this test by each country I have cut and pasted the relevant paragraph of Chapter 2.3.13 of the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals as it discusses the standardization of the IHC test for BSE:
"In conjunction with, or even as an alternative to, the histopathological evaluation of medulla sections is the use of IHC to detect PrPres accumulation in formalin-fixed, paraffin-embedded material (47, 94). Several protocols have been applied successfully to the IHC detection of PrP for the diagnosis of BSE (44, 47, 54, 94). Harmonisation toward a fully validated standardised routine diagnostic IHC method is desirable. However, it is likely that only the general principles can be prescribed, with precise methods being determined by each individual laboratory. A European Commission (EC) funded collaboration among European laboratories, which addressed the need for harmonisation of diagnostic methods, concluded that the total standardisation of methods was difficult and possibly unnecessary. Local conditions will always dictate a degree of inter-laboratory variation, and each method should be optimised for use with the standard tissues and common reagents (such as water) used locally. Historically there has also been a dependence on 'in-house' polyclonal antibodies, but the increase in commercially available monoclonal antibodies has reduced this variation significantly. It is much more important to achieve a standardised output, as monitored by participation in QA exercises, and by comparison with the results of a standardised model method."
The CFIA is aware of differences in the testing of BSE in Canada and the US. In dialogues with the US, the CFIA continues to detail the reagents that we use and believe are appropriate to use in the diagnosis of the United States. Nonetheless, the decision on the reagents used in the laboratory diagnosis of BSE is ultimately the choice of the individual member countries.
In Sandy Russel's report on the Alberta Beef Industry Conference, Dr. Joyce VanDonkersgoed (AB Verified Beef program)was asked "If our industries are so linked why are we finding BSE cases and the US is not even though they have tested a higher number of animals?` Her comment was the "gold standard" tests (final confirmatory tests) in Canada and the US are different. She said the US version uses a test with 1 micoclonal antibody, compared to Canada's test which uses 15 microclonal antibodies. This could account for the difference.
The CFIA was asked to explain why Canada and the US would use different standards and why this has not been a issue in the debate over Canada being a source of BSE and the US is clean according to some of the opposition to the opening of the US border to Canadian cattle.
Following is the reply:
-----Original Message-----
From: Penny Greenwood [mailtogreenwood@inspection.gc.ca]
Sent: Wednesday, March 16, 2005 1:58 PM
To: jarmstrong@agr.gov.sk.ca
Cc: Nancy Lalonde; Marlene Longtin; <
Subject: Re: Testing for BSE- Canada and US proceedures: WEB RESPONSE / RÉPONSE DU WEB ID:2005/3-603
The international standard setting body for animal health and zoosanitary status is the OIE. This body sets the standards for conditions for countries to claim a particular disease status (eg. free) for specific diseases, stipulates conditions for trade in affected commodities (animals, semen, meat, etc), surveillance and also for diagnostic methodologies used to detect these diseases.
A member country could certainly debate the appropriateness of another member country's testing if they were not following the recommendations made in the OIE code and associated documentation.
Both the US and Canada utilize immunohistochemistry (IHC) as the gold standard test for BSE. In response to your comments regarding the antibodies used in this test by each country I have cut and pasted the relevant paragraph of Chapter 2.3.13 of the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals as it discusses the standardization of the IHC test for BSE:
"In conjunction with, or even as an alternative to, the histopathological evaluation of medulla sections is the use of IHC to detect PrPres accumulation in formalin-fixed, paraffin-embedded material (47, 94). Several protocols have been applied successfully to the IHC detection of PrP for the diagnosis of BSE (44, 47, 54, 94). Harmonisation toward a fully validated standardised routine diagnostic IHC method is desirable. However, it is likely that only the general principles can be prescribed, with precise methods being determined by each individual laboratory. A European Commission (EC) funded collaboration among European laboratories, which addressed the need for harmonisation of diagnostic methods, concluded that the total standardisation of methods was difficult and possibly unnecessary. Local conditions will always dictate a degree of inter-laboratory variation, and each method should be optimised for use with the standard tissues and common reagents (such as water) used locally. Historically there has also been a dependence on 'in-house' polyclonal antibodies, but the increase in commercially available monoclonal antibodies has reduced this variation significantly. It is much more important to achieve a standardised output, as monitored by participation in QA exercises, and by comparison with the results of a standardised model method."
The CFIA is aware of differences in the testing of BSE in Canada and the US. In dialogues with the US, the CFIA continues to detail the reagents that we use and believe are appropriate to use in the diagnosis of the United States. Nonetheless, the decision on the reagents used in the laboratory diagnosis of BSE is ultimately the choice of the individual member countries.
Comment